Mazdutide: China Approval, Weight-Loss Evidence and Safety Limits

Mazdutide is a GLP-1 and glucagon receptor dual agonist, also known in the literature as IBI362 or LY3305677. It matters because it is not just another rumored weight-loss peptide. It has published human studies in Chinese adults, a phase 3 obesity paper in the New England Journal of Medicine, and a China approval record from 2025.

That does not make it a US-approved option. As of June 10, 2026, mazdutide does not have a US FDA-approved prescribing label. For readers in the United States, the practical distinction is sharp: mazdutide has credible clinical evidence, but it is not a legally prescribed FDA-approved obesity medication like semaglutide or tirzepatide.

Mazdutide also sits in a crowded pipeline. Compare it with survodutide, retatrutide, cagrilintide, and the broader peptides for weight loss guide. If you are comparing drug duration or repeated-dose behavior, the peptide half-life guide and accumulation calculator are useful background.

This guide is educational and not medical advice. Mazdutide is a prescription drug in China and an investigational or unavailable drug in many other markets. Do not treat trial dosing, research-vial content or online protocols as personal medical instructions.

Mazdutide At A Glance

How Mazdutide Works

Mazdutide is built around two incretin-adjacent pathways: GLP-1 receptor activation and glucagon receptor activation. GLP-1 receptor agonism is familiar from Ozempic, Wegovy, Saxenda and other approved GLP-1 drugs. It can reduce appetite, slow gastric emptying early in treatment and improve glucose handling.

The glucagon receptor side is the differentiator. Glucagon receptor activation is being studied because it may increase energy expenditure and affect liver metabolism, but it also creates a more complicated safety and tolerability question. Glucagon is not simply a weight-loss switch. It is a counterregulatory hormone involved in glucose and hepatic metabolism.

That is why mazdutide should not be described as "stronger semaglutide." It is a different dual agonist. A better comparison is:

For a wider approved-drug list, use the GLP-1 drugs list. For a direct approved-drug comparison, use semaglutide vs tirzepatide.

What The Early Human Studies Showed

The first mazdutide studies were not large outcome trials. They were early randomized phase 1b studies designed to evaluate tolerability, pharmacology and initial metabolic signals.

One phase 1b trial in Chinese adults with type 2 diabetes studied once-weekly IBI362 at 3.0, 4.5 and 6.0 mg for 12 weeks. PubMed lists the trial as a randomized, placebo-controlled study. The abstract reports reductions in HbA1c, fasting plasma glucose and post-meal glucose measures, with diarrhea, decreased appetite and nausea among common treatment-emergent adverse events.

Another phase 1b study in Chinese adults with overweight or obesity evaluated multiple ascending doses. That study helps explain why mazdutide attracted weight-loss attention before late-stage results were available. It was still an early trial, with short duration and a limited sample compared with phase 3 obesity programs.

A later multiple-ascending-dose study tested higher 9 mg and 10 mg dose levels in Chinese adults with overweight or obesity. The title itself signals the key interpretation point: safety and efficacy at higher doses were being explored, not proven for every patient population or every market.

The 2025 Phase 3 Obesity Paper

The most important mazdutide clinical publication so far is the 2025 New England Journal of Medicine paper titled "Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight." It moved the conversation from early dose finding toward a larger phase 3 obesity dataset.

That phase 3 result is why mazdutide deserves dedicated coverage rather than a single mention in a pipeline roundup. It also explains why readers compare it with survodutide, retatrutide and approved GLP-1 medications.

The cautious reading is still necessary. The published phase 3 population was Chinese adults with obesity or overweight. Cross-trial comparisons against Zepbound, Wegovy, retatrutide or survodutide can be useful for orientation, but they are not the same as a head-to-head trial. Different populations, dose schedules, endpoints and trial designs can change the numbers.

China Approval Does Not Mean FDA Approval

China's National Medical Products Administration approved mazdutide injection in 2025. That is a real regulator milestone, not just a company pipeline update. It means mazdutide crossed a formal approval threshold in China.

For US readers, the label distinction matters more than the headline. A China approval does not create a US prescribing label, US pharmacy availability or US insurance coverage. It also does not validate research-vial products sold with "for research use" disclaimers.

Use this status map:

That status distinction should shape every practical claim. Mazdutide can be discussed as a studied dual agonist and China-approved drug. It should not be presented as an available US treatment protocol.

Side Effects And Safety Signals

Published mazdutide studies point to a familiar incretin tolerability pattern: gastrointestinal symptoms such as nausea, diarrhea, reduced appetite and related events appear in the clinical trial record. The early type 2 diabetes trial also reported diarrhea and decreased appetite as common treatment-emergent events.

This is not surprising for a GLP-1-pathway drug, but mazdutide's glucagon component means it should not be treated as identical to semaglutide. The right safety comparison asks:

• What dose was used?
• Was the dose escalated?
• What population was enrolled?
• Were participants living with type 2 diabetes, obesity, liver disease or other metabolic conditions?
• Did the study measure liver, glucose, heart rate, gallbladder or pancreatic outcomes?
• Was the source an approved product, clinical trial material or unregulated research vial?

For class-level background on nausea, vomiting, constipation, pancreatitis warnings and when to call a clinician, read GLP-1 side effects. Do not assume that a side effect list from one GLP-1 drug fully captures every mazdutide-specific risk.

Mazdutide vs Survodutide

Mazdutide and survodutide are easy to confuse because both are discussed as GLP-1/glucagon dual agonists. The distinction is development context and data package.

Survodutide is being developed by Boehringer Ingelheim and Zealand Pharma, with major attention on obesity and MASH. The survodutide guide covers its obesity and liver-disease data in detail. Mazdutide has a China-focused development story with Innovent and Lilly roots, published Chinese trials and China approval.

The overlap is the mechanism category. The search intent is different: readers looking up mazdutide usually want to know whether it is "China's GLP-1" and how its evidence compares with approved incretin drugs. Readers looking up survodutide often want MASH, liver-fat and phase 3 obesity context.

Mazdutide vs Retatrutide

Retatrutide is a triple agonist: GIP, GLP-1 and glucagon. Mazdutide is a dual agonist: GLP-1 and glucagon. That means mazdutide lacks the GIP receptor component that defines tirzepatide and retatrutide.

The temptation is to rank pipeline drugs by headline weight-loss percentage. That is too thin. Approval status, population, trial length, tolerability, manufacturing controls and label warnings matter. Retatrutide may have larger headline weight-loss numbers in some trials, but it remains investigational. Mazdutide has China approval, but not a US label.

Use retatrutide vs GLP-1 and tirzepatide vs retatrutide if you are mapping the difference between approved dual agonists, triple agonists and pipeline mechanisms.

How To Evaluate Mazdutide Claims

Mazdutide claims online usually fall into a few buckets:

Forum discussion can help identify common questions: China approval, vendor claims, dual-agonist mechanism, and comparisons with retatrutide or survodutide. It should not be used as proof of efficacy or safety.

Where Mazdutide Fits

Mazdutide is best understood as a serious GLP-1/glucagon drug with a China-first regulatory story. It is more evidence-backed than most peptide market names, but less practically relevant for US treatment decisions than FDA-approved options.

For now, the most useful PeptideStat framing is:

• Mazdutide is not a generic replacement for Wegovy or Zepbound.
• Mazdutide is not the same as retatrutide.
• Mazdutide is not interchangeable with survodutide, even though both activate GLP-1 and glucagon receptors.
• China approval should not be confused with US approval.
• Published clinical trials matter more than vendor claims or social anecdotes.

Bottom Line

Mazdutide deserves attention because it has crossed a meaningful evidence and regulatory threshold: human trials, phase 3 obesity data and China approval. It is one of the more important GLP-1/glucagon dual agonists to understand.

The boundary is just as clear. Mazdutide is not FDA approved as of June 10, 2026, and research-market products should not be treated as regulated medicine. The honest angle is not hype. It is a China-approved dual agonist with real human evidence, real safety questions and limited practical availability in the United States.

References

1. Jiang H, et al. A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes.

2. Ji L, et al. Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: a randomised, placebo-controlled, multiple-ascending-dose phase 1b trial.

3. Ji L, et al. IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: a randomised, placebo-controlled, multiple ascending dose phase 1b study.

4. Ji L, et al. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. New England Journal of Medicine.

5. National Medical Products Administration. Announcement approving mazdutide injection for marketing in China.